Related Experiment Videos
Therapeutic options in renal cell carcinoma
1Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510.
Seminars in Oncology
|February 1, 1989
Summary
Renal cell carcinoma management is challenging. While surgery offers cure for localized disease, new biologic therapies like interferon and interleukin-2 show modest promise for metastatic cases.
Area of Science:
- Oncology
- Urology
- Immunotherapy
Background:
- Renal cell carcinoma (RCC) presents significant management challenges.
- Surgery is the sole curative option for localized RCC; adjuvant therapies offer no additional benefit.
- Metastatic RCC typically carries a poor prognosis, necessitating novel therapeutic strategies.
Purpose of the Study:
- To review current therapeutic approaches for renal cell carcinoma.
- To evaluate the efficacy of biologic response modifiers in metastatic RCC.
- To explore mechanisms of resistance to cancer therapies.
Main Methods:
- Review of existing literature on RCC treatment modalities.
- Analysis of clinical trial data for interferon and interleukin-2 in metastatic RCC.
- Discussion of resistance mechanisms to cytotoxic drugs and biologic response modifiers.
Main Results:
- Surgery remains the mainstay for localized RCC.
- Interferon and interleukin-2 have demonstrated modest improvements in metastatic RCC.
- Understanding resistance mechanisms is crucial for future treatment development.
Conclusions:
- Current treatments for advanced RCC are limited.
- Biologic response modifiers represent a modest advancement for metastatic disease.
- Further research into resistance mechanisms will enable more effective RCC therapies.